Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2409212 | Vaccine | 2007 | 8 Pages |
Abstract
A majority of cervical cancers are associated with Human Papillomavirus (HPV)-16. A DNA vaccine (E7IR) was designed for prophylactic and therapeutic treatment of HPV-16+ tumors containing two repeats of the E7 gene to inactivate transformation and duplicate available epitopes. Mice were vaccinated then tumor challenged, or challenged and then immunized and monitored for tumor volume and survival. Splenocytes were utilized for in vivo CTL assays. The E7IR vaccine demonstrated decreased tumor volume and enhanced survival in prophylactic and therapeutic experiments and improved CTL-mediated lysis. The E7IR vaccine shows promise in prevention of tumor formation and elimination of established tumors.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Joeli A. Brinkman, Xuemei Xu, W. Martin Kast,